Ori Biotech, based in London, has significant potential due to its focus on improving the manufacturing process for lifesaving treatments. By addressing inefficiencies and delays in traditional methods, Ori Biotech aims to make critical therapies more accessible and timely for patients. The company's advanced technology and specialized manufacturing capabilities set it apart, positioning it to meet growing demands in healthcare. Supported by investors like Kindred Capital and Octopus Ventures, Ori Biotech has the resources needed to disrupt the market and deliver substantial value to its business-to-business clients.